Review 1: "Transient JAK/STAT Inhibition by Ruxolitinib Modulates Malaria-specific CD4+ T Cell Responses and Enhances Recall Immunity in Volunteers Experimentally Infected with Plasmodium Falciparum"
Year: 2025
Type: peer-review
Abstract: Reviewers found the preprint's evidence to be between potentially informative to reliable. Although reviewers found the clinical data to be encouraging to support the ability of ruxolitinib to control malaria, they had concerns regarding the proposed mechanism.
Author: Henrique Borges da Silva
Institution: Mayo Clinic
Language: English
Topic: Malaria Research and Control
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7131679472